Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in metastatic nasopharyngeal carcinoma
NCT02698111Phase 2Terminated
- Sponsor
- Zelgen
- Start
- Feb 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib in nasopharyngeal carcinoma (NPC), sponsored by Zelgen. Started Feb 2017; status: terminated.
02
Drugs
donafenib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02698111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698111.